NTRK1

High affinity nerve growth factor receptor

260,282 patent compounds predicted against NTRK1, 163,176 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL57294	0.51	20/20
SCHEMBL56576	0.51	20/20
SCHEMBL56800	0.79	19/20
SCHEMBL56454	0.56	19/20
SCHEMBL57147	0.56	19/20
SCHEMBL57628	0.66	18/20
SCHEMBL56685	0.63	17/20
SCHEMBL56686	0.63	17/20
SCHEMBL57380	0.62	17/20
SCHEMBL57981	0.59	17/20
SCHEMBL57982	0.59	17/20
SCHEMBL57129	0.58	17/20
SCHEMBL57130	0.58	17/20
SCHEMBL57234	0.54	17/20
SCHEMBL56561	0.54	17/20
SCHEMBL56562	0.54	17/20
SCHEMBL56396	0.53	17/20
SCHEMBL57051	0.51	17/20
SCHEMBL57691	0.78	16/20
SCHEMBL57226	0.69	16/20

Germline variants in NTRK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full NTRK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to NTRK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors	PHASE2	RECRUITING
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors	PHASE2	COMPLETED
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities	PHASE1/PHASE2	RECRUITING
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer	PHASE2	WITHDRAWN
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors	PHASE2	RECRUITING
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients	PHASE2	RECRUITING
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	PHASE1/PHASE2	RECRUITING
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	PHASE2	ACTIVE_NOT_RECRUITING
Study of FCN-098 in Patients With Advanced Solid Tumor	PHASE1	UNKNOWN
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers	PHASE1	ENROLLING_BY_INVITATION
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma	PHASE1	COMPLETED
AZD7451 for Recurrent Gliomas	PHASE1	COMPLETED
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer	PHASE1	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion	nan	COMPLETED
Association of Urine BDNF and NGF With Lower Urinary System Parameters	nan	RECRUITING
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion	nan	APPROVED_FOR_MARKETING
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion	nan	NO_LONGER_AVAILABLE
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.	nan	ACTIVE_NOT_RECRUITING
Spanish Study for Molecular Characterization of Thyroid Carcinoma	nan	ACTIVE_NOT_RECRUITING
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NTRK1 binder may also engage these)

Protein	Name	Similarity
Q3UFB7	—	0.996	Q3UFB7 →
P35739	—	0.994	P35739 →
Q91009	—	0.990	Q91009 →
AXL	Tyrosine-protein kinase receptor UFO	0.975	landscape →
PKN1	Serine/threonine-protein kinase N1	0.966	landscape →
Q60553	—	0.966	Q60553 →
Q00993	—	0.965	Q00993 →
A1A4I4	—	0.965	A1A4I4 →
D4ABX8	—	0.965	D4ABX8 →
P70268	—	0.965	P70268 →
Q95126	—	0.962	Q95126 →
P27040	—	0.962	P27040 →
Q1WIM1	—	0.961	Q1WIM1 →
O95294	—	0.961	O95294 →
Q80XU8	—	0.961	Q80XU8 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.961	landscape →
Q9Z268	—	0.960	Q9Z268 →
Q63433	—	0.960	Q63433 →
Q61526	—	0.960	Q61526 →
Q62799	—	0.960	Q62799 →
ACVR2B	Activin receptor type-2B	0.960	landscape →
Q5E9Z9	—	0.960	Q5E9Z9 →
O75325	—	0.960	O75325 →
Q4R8Y9	—	0.960	Q4R8Y9 →
Q9P2J2	—	0.959	Q9P2J2 →
NECTIN4	Nectin-4	0.959	landscape →
Q8R464	—	0.958	Q8R464 →
Q5STE3	—	0.958	Q5STE3 →
ERBB3	Receptor tyrosine-protein kinase erbB-3	0.958	landscape →
P38445	—	0.958	P38445 →